Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Effect of zamicastat, a dopamine beta-hydroxylase inhibitor, on the monocrotaline rat model of pulmonary arterial hypertension

Eduardo Moura, Cristina Costa, Bruno Igreja, Nuno Pires, Vânia Batalha, Maria-Joao Bonifacio, Patricio Soares-Da-Silva
European Respiratory Journal 2020 56: 3560; DOI: 10.1183/13993003.congress-2020.3560
Eduardo Moura
1Research & Development, BIAL, Portela & Cª, S.A. , Coronado (S Mamede e S Romão), Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: eduardo.moura@bial.com
Cristina Costa
1Research & Development, BIAL, Portela & Cª, S.A. , Coronado (S Mamede e S Romão), Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Bruno Igreja
1Research & Development, BIAL, Portela & Cª, S.A. , Coronado (S Mamede e S Romão), Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nuno Pires
1Research & Development, BIAL, Portela & Cª, S.A. , Coronado (S Mamede e S Romão), Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vânia Batalha
1Research & Development, BIAL, Portela & Cª, S.A. , Coronado (S Mamede e S Romão), Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria-Joao Bonifacio
1Research & Development, BIAL, Portela & Cª, S.A. , Coronado (S Mamede e S Romão), Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patricio Soares-Da-Silva
2Research & Development, BIAL, Portela & Cª, S.A., Coronado (S Mamede e S Romão); Biomedicine Dept., Unit of Pharmacology & Therapeutics, Faculty of Medicine, University of Porto; MedInUPCenter for Drug Discovery and Innovative Medicines, University of Porto, Porto, Portugal
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Pulmonary arterial hypertension (PAH) is a group of rare diseases characterized by elevated pulmonary arterial resistance leading to right ventricle hypertrophy and failure. Studies of PAH patients show that hyperstimulation of the sympathetic nervous system appears to contribute to the development of the condition (Velez-Roa S. et al Circulation 2004, 110:1308–1312).

The aim of this study was to evaluate the effect of Zamicastat, a reversible inhibitor of dopamine β-hydroxylase (DβH; EC 1.14.17.1), on the rat monocrotaline (MCT) model of PAH.

PAH model was induced in male Wistar Han rats with a subcutaneous administration of MCT (60 mg/kg). Twelve days after, when the increase in right ventricular pressure has been established, daily treatment with Zamicastat (30 mg/kg/day) was initiated and prolonged until day 27 or 25, when surviving animals were evaluated respectively for catecholamine levels or right ventricular systolic pressure.

Zamicastat significantly improved the survival rate of MCT-treated animals. This was associated with a significant decrease in sympathetic activity, as shown by a reduction in noradrenaline (NE) levels in the urine and by a significant decrease in NE tissue content in the ventricles. Interestingly no effect of Zamicastat on the MCT-induced increase in right ventricle systolic pressure was observed.

Therapeutic administration of Zamicastat, and consequent decrease of NE, although not altering high right ventricular pressure, is effective in significantly improving rat survival in the PAH MCT model. This suggests that the beneficial effect of Zamicastat is exerted by a mechanism other than decreasing right ventricular pressure.

  • Experimental approaches
  • Pulmonary hypertension
  • Orphan diseases

Footnotes

Cite this article as: European Respiratory Journal 2020; 56: Suppl. 64, 3560.

This abstract was presented at the 2020 ERS International Congress, in session “Respiratory viruses in the "pre COVID-19" era”.

This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

  • Copyright ©the authors 2020
Previous
Back to top
Vol 56 Issue suppl 64 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Effect of zamicastat, a dopamine beta-hydroxylase inhibitor, on the monocrotaline rat model of pulmonary arterial hypertension
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Effect of zamicastat, a dopamine beta-hydroxylase inhibitor, on the monocrotaline rat model of pulmonary arterial hypertension
Eduardo Moura, Cristina Costa, Bruno Igreja, Nuno Pires, Vânia Batalha, Maria-Joao Bonifacio, Patricio Soares-Da-Silva
European Respiratory Journal Sep 2020, 56 (suppl 64) 3560; DOI: 10.1183/13993003.congress-2020.3560

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Effect of zamicastat, a dopamine beta-hydroxylase inhibitor, on the monocrotaline rat model of pulmonary arterial hypertension
Eduardo Moura, Cristina Costa, Bruno Igreja, Nuno Pires, Vânia Batalha, Maria-Joao Bonifacio, Patricio Soares-Da-Silva
European Respiratory Journal Sep 2020, 56 (suppl 64) 3560; DOI: 10.1183/13993003.congress-2020.3560
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Mild PH and premature mortality in a cohort undergoing routine echocardiography
  • Late Breaking Abstract - COVID-19 in patients with pulmonary hypertension: a national prospective cohort study
  • Risk assessment in Pulmonary Arterial Hypertension (PAH) based on the Simplified French Model: A single centre experience
Show more Pulmonary hypertension

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society